Contineum Therapeutics, Inc. (NASDAQ: CTNM) announced on September 14, 2026, that the Phase 2 MOONLIGHT-1 clinical trial for JNJ-5120/PIPE-307 did not achieve its primary efficacy endpoint. The trial evaluated the efficacy, safety, and tolerability of the drug candidate as a monotherapy in adult participants with major depressive disorder (MDD).
The MOONLIGHT-1 study was a randomized, double-blind, multicenter, placebo-controlled trial designed to assess improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5. According to the press release included in the filing, the trial failed to meet this primary measure of efficacy.
The company stated that JNJ-5120/PIPE-307 was well-tolerated during the study with no new safety signals observed. Johnson & Johnson, which is developing the candidate under a global license and development agreement with Contineum, is currently evaluating the trial data. The company noted that analyses of the data, including prespecified exploratory endpoints, are ongoing.
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on oral small molecule therapies for inflammatory and fibrotic diseases. The company is advancing a pipeline of internally-developed programs, including PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain.
